Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   43932   clinical trials with a EudraCT protocol, of which   7307   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    Pharmacological treatment of hypersexual disorder; an open pilot study to evaluate the feasibility and effectiveness of treatment with Naltrexone

    Summary
    EudraCT number
    2018-001049-15
    Trial protocol
    SE  
    Global end of trial date
    29 Sep 2019

    Results information
    Results version number
    v1(current)
    This version publication date
    12 Jun 2021
    First version publication date
    12 Jun 2021
    Other versions

    Trial information

    Close Top of page
    Trial identification
    Sponsor protocol code
    HD-TREX
    Additional study identifiers
    ISRCTN number
    -
    US NCT number
    -
    WHO universal trial number (UTN)
    -
    Sponsors
    Sponsor organisation name
    ANOVA Karolinska University Hopsital
    Sponsor organisation address
    Norra Stationsgatan 69, Stockholm, Sweden,
    Public contact
    Josephine Savard, ANOVA (Andrologi, Sexualmedicin, Transmedicin), 46 851773200, josephine.savard@sll.se
    Scientific contact
    Josephine Savard, ANOVA (Andrologi, Sexualmedicin, Transmedicin), 46 851773200, josephine.savard@sll.se
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    14 Apr 2020
    Is this the analysis of the primary completion data?
    Yes
    Primary completion date
    29 Sep 2019
    Global end of trial reached?
    Yes
    Global end of trial date
    29 Sep 2019
    Was the trial ended prematurely?
    No
    General information about the trial
    Main objective of the trial
    The aim of this pilot study is to assess feasibility, efficacy and tolerability of Naltrexone treatment in patients with hypersexual disorder. The following research questions will be asked: 1. Is treatment with Naltrexone feasible for patients with Hypersexual disorder treated at a sub specialized unit? 2. Does Naltrexone reduce symptoms in patients with Hypersexual disorder? And if so, what clinical characteristics predict response? 3. What is the tolerability of Naltrexone in patients with Hypersexual disorder?
    Protection of trial subjects
    Blood chemistry and adverse event monitoring
    Background therapy
    -
    Evidence for comparator
    -
    Actual start date of recruitment
    01 Sep 2018
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    No
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    Sweden: 20
    Worldwide total number of subjects
    20
    EEA total number of subjects
    20
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    20
    From 65 to 84 years
    0
    85 years and over
    0

    Subject disposition

    Close Top of page
    Recruitment
    Recruitment details
    Patients seeking treatment due to troubled sexual behavior

    Pre-assignment
    Screening details
    37 men were screened, 20 were recrutied, 17 did not beet inclusion criteria mainly due to not meeting diagnose criteria

    Pre-assignment period milestones
    Number of subjects started
    20
    Number of subjects completed
    20

    Period 1
    Period 1 title
    overall trial (overall period)
    Is this the baseline period?
    Yes
    Allocation method
    Not applicable
    Blinding used
    Not blinded

    Arms
    Arm title
    main arm
    Arm description
    -
    Arm type
    Experimental

    Investigational medicinal product name
    naltrexone
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Coated tablet
    Routes of administration
    Oral use
    Dosage and administration details
    25-50 mg daily use

    Number of subjects in period 1
    main arm
    Started
    20
    Completed
    20

    Baseline characteristics

    Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    overall trial
    Reporting group description
    -

    Reporting group values
    overall trial Total
    Number of subjects
    20 20
    Age categorical
    Units: Subjects
        In utero
    0 0
        Preterm newborn infants (gestational age < 37 wks)
    0 0
        Newborns (0-27 days)
    0 0
        Infants and toddlers (28 days-23 months)
    0 0
        Children (2-11 years)
    0 0
        Adolescents (12-17 years)
    0 0
        Adults (18-64 years)
    20 20
        From 65-84 years
    0 0
        85 years and over
    0 0
    Gender categorical
    Units: Subjects
        Female
    0 0
        Male
    20 20
    Subject analysis sets

    Subject analysis set title
    full anaysis
    Subject analysis set type
    Full analysis
    Subject analysis set description
    all subjects

    Subject analysis sets values
    full anaysis
    Number of subjects
    20
    Age categorical
    Units: Subjects
        In utero
    0
        Preterm newborn infants (gestational age < 37 wks)
    0
        Newborns (0-27 days)
    0
        Infants and toddlers (28 days-23 months)
    0
        Children (2-11 years)
    0
        Adolescents (12-17 years)
    0
        Adults (18-64 years)
    20
        From 65-84 years
    0
        85 years and over
    0
    Age continuous
    Units:
        
    ±
    Gender categorical
    Units: Subjects
        Female
    0
        Male
    20

    End points

    Close Top of page
    End points reporting groups
    Reporting group title
    main arm
    Reporting group description
    -

    Subject analysis set title
    full anaysis
    Subject analysis set type
    Full analysis
    Subject analysis set description
    all subjects

    Primary: main end point

    Close Top of page
    End point title
    main end point
    End point description
    End point type
    Primary
    End point timeframe
    after 4 weeks of treatment
    End point values
    main arm full anaysis
    Number of subjects analysed
    20
    20
    Units: 0-24 units
    1
    1
    Statistical analysis title
    paired sample t-test
    Statistical analysis description
    Longitudinal data of same group (n=20) at two time points
    Comparison groups
    main arm v full anaysis
    Number of subjects included in analysis
    40
    Analysis specification
    Pre-specified
    Analysis type
    equivalence
    P-value
    < 0.05
    Method
    t-test, 2-sided
    Parameter type
    Mean difference (final values)
    Point estimate
    5.95
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    3.9
         upper limit
    8
    Variability estimate
    Standard deviation

    Adverse events

    Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    After 3-5 days with medication, weekly in the web-based plattform and at a consultation after 4 weeks. After 8 weeks (follow-up) adverse events were assessed. Bloodsamples were collected at baseline and after 4 weeks.
    Assessment type
    Systematic
    Dictionary used for adverse event reporting
    Dictionary name
    PI designed
    Dictionary version
    1
    Reporting groups
    Reporting group title
    sponsor
    Reporting group description
    -

    Serious adverse events
    sponsor
    Total subjects affected by serious adverse events
         subjects affected / exposed
    0 / 20 (0.00%)
         number of deaths (all causes)
    0
         number of deaths resulting from adverse events
    0
    Frequency threshold for reporting non-serious adverse events: 5%
    Non-serious adverse events
    sponsor
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    19 / 20 (95.00%)
    Nervous system disorders
    Fatigue
         subjects affected / exposed
    11 / 20 (55.00%)
         occurrences all number
    11
    Vertigo
         subjects affected / exposed
    6 / 20 (30.00%)
         occurrences all number
    6
    Apathy
         subjects affected / exposed
    3 / 20 (15.00%)
         occurrences all number
    3
    Headache
         subjects affected / exposed
    2 / 20 (10.00%)
         occurrences all number
    2
    Nightmare
         subjects affected / exposed
    1 / 20 (5.00%)
         occurrences all number
    1
    Gastrointestinal disorders
    Nausea
         subjects affected / exposed
    6 / 20 (30.00%)
         occurrences all number
    6
    Abdominal pain
         subjects affected / exposed
    6 / 20 (30.00%)
         occurrences all number
    6
    Weight decreased
         subjects affected / exposed
    1 / 20 (5.00%)
         occurrences all number
    1
    Flatulence
         subjects affected / exposed
    1 / 20 (5.00%)
         occurrences all number
    1
    Diarrhoea
         subjects affected / exposed
    1 / 20 (5.00%)
         occurrences all number
    1
    Constipation
         subjects affected / exposed
    1 / 20 (5.00%)
         occurrences all number
    1
    Reproductive system and breast disorders
    Sexual dysfunction
         subjects affected / exposed
    2 / 20 (10.00%)
         occurrences all number
    2
    Psychiatric disorders
    Anxiety
         subjects affected / exposed
    2 / 20 (10.00%)
         occurrences all number
    2
    Depressed mood
         subjects affected / exposed
    1 / 20 (5.00%)
         occurrences all number
    1
    Musculoskeletal and connective tissue disorders
    Back pain
         subjects affected / exposed
    1 / 20 (5.00%)
         occurrences all number
    1
    Infections and infestations
    Rhinitis
         subjects affected / exposed
    1 / 20 (5.00%)
         occurrences all number
    1

    More information

    Close Top of page

    Substantial protocol amendments (globally)

    Were there any global substantial amendments to the protocol? No

    Interruptions (globally)

    Were there any global interruptions to the trial? No

    Limitations and caveats

    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    None reported

    Online references

    http://www.ncbi.nlm.nih.gov/pubmed/32532705
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA